UNSPSC 51432408: Zofenoprilat arginine

This classification denotes an ace inhibitor with the molecular formula C15H19NO3S2.C6H14N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36F26ZSQ0D. The term zofenoprilat arginine is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule zofenoprilat arginine under HS 29339990 and SITC 51577. As of Q4 2014, ZOFENOPRILAT ARGININE remains US FDA's Preferred Term for this commodity. Zofenoprilat arginine bears US NLM identifiers UMLS ID C0646135 and NCI Concept Code C66700.

SMILES: C[C@H](CS)C(=O)N1C[C@H](C[C@H]1C(=O)O)SC2CCCCC2.C(C[C@@H](C(=O)O)N)CNC(=N)N.

UNSPSC 51432408 Zofenoprilat arginine, a Commodity code, represents a narrow pharmaceutical ingredient that state and local procurement offices rarely solicit in isolation; instead, recent activity shows these jurisdictions buying advanced life support medications and generic pharmaceuticals through broader multi-item contracts and cooperative purchasing agreements where individual drug codes are specified by National Drug Code (NDC) rather than by UNSPSC commodity designation. The work state and local governments actually buy under this code involves emergency medical services supply contracts, pharmacy benefit program expansion initiatives, and multi-state cooperative procurement agreements that encompass hundreds of pharmaceutical line items, with delivery, expiration-date warranty, inventory management, and safety documentation (Safety Data Sheets, accessibility reports) as standard contract requirements. The issuing bodies include municipal fire and emergency services departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance), indicating that pharmaceutical procurement flows through both direct municipal procurement and state-level consolidated purchasing vehicles that span multiple jurisdictions.

Recent activity centers on Florida, Texas, and Minnesota with Oregon participation through the MMCAP cooperative. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) in April 2026 for Advanced Life Support Medications—including four specific medication line items totaling over 3,500 units with a nine-month minimum expiration requirement and 365-day warranty—due April 8, 2026, with an estimated contract value of $40,000 and a Small Local Business Enterprise 5 percent bid discount available. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP (S1070000015802) in January 2026 for Generic Multi Source Pharmaceuticals and OTC Products with responses due March 26, 2026; this cooperative procurement required NDC-specific pricing through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC) with contract effectiveness July 1, 2026. The Texas HHS Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capability information for a Direct-to-Manufacturer Prescriptions program, indicating upstream market research before formal procurement.